无容量
易普利姆玛
医学
肿瘤科
内科学
肺癌
成本效益
临床试验
成本效益分析
癌症
免疫疗法
风险分析(工程)
作者
Yamin Shu,Yiling Ding,Feie Li,Qilin Zhang
标识
DOI:10.1016/j.intimp.2022.109589
摘要
First-line nivolumab plus ipilimumab treatment for advanced NSCLC was found to be not cost-effective compared with chemotherapy at a WTP threshold of $37,663.26/QALY in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI